Drug Profile
Duvortuxizumab - MacroGenics
Alternative Names: Anti-CD3/CD19 monoclonal-antibody; CD3-CD19 DART protein; CD3xCD19 DART molecule; JNJ-64052781; MGD 011Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer Janssen Biotech; MacroGenics
- Class Bispecific antibodies
- Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma
Most Recent Events
- 31 Aug 2017 Discontinued - Phase-I for Haematological malignancies (Second-line therapy or greater) in France, Israel, Spain, Belgium (IV)
- 31 Aug 2017 Janssen terminates a phase I trial in Haematological malignancies (Second-line therapy or greater) in USA, Spain, Israel, France, Belgium due to treatment-related neurotoxicity (IV) (NCT02454270) (EudraCT2015-000485-63)
- 31 Aug 2017 Janssen Biotech terminates its licence for duvortuxizumab